Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Pakistan Journal of Pharmaceutical Sciences. 2018; 31 (3 Supp.): 1039-1044
en Inglés | IMEMR | ID: emr-198714

RESUMEN

Pakistan is categorized to below to middle income countries where two third of the national annual health expenditure is in the form of out of pocket [OOP] cost. A prevalence based study was conducted to determine the OOP cost treatment of hypertension in Karachi by interviewing 350 hypertensive patients aged >30 years through a validated questionnaire. Hypertension [HTN] was classified into stage 1 and stage 2 and was found to be common in females [53.42%] than males [46.57%]. The total costs of stage 1and stage 2 HTN were calculated to be217869.7PKR and17545457.6 PKR respectively. The average treatment cost of stage 1 was observed to be significantly lower [p=0.006] than the cost of stage 2 HTN. Moreover; the cost of antihypertensive drugs, physician fees and laboratory tests were considerably different however; no variation was seen in cost of transport and loss of productivity through absenteeism from work. Overall, the present study indicates that the antihypertensive treatment has imposed a high burden on the pocket of common man and this is a major reason for treatment non-adherence. Consequently, it increases the risks of cardiovascular events, morbidity and mortality. Therefore, effective strategic planning is need of time to reduce OOP cost for better control on hypertension in Pakistan

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA